dc.creatorPelegrini
dc.creatorMarina Dal'Bo; Pereira
dc.creatorJuliana Biar; Costa
dc.creatorSolange dos Santos; Salazar Terreros
dc.creatorMyriam Janeth; Degrossoli
dc.creatorAdriana; Giorgio
dc.creatorSelma
dc.date2016
dc.datejul
dc.date2017-11-13T13:43:50Z
dc.date2017-11-13T13:43:50Z
dc.date.accessioned2018-03-29T05:58:34Z
dc.date.available2018-03-29T05:58:34Z
dc.identifierAsian Pacific Journal Of Tropical Medicine. Elsevier Sci Ltd, v. 9, p. 633 - 638, 2016.
dc.identifier1995-7645
dc.identifierWOS:000378577500006
dc.identifier10.1016/j.apjtm.2016.05.018
dc.identifierhttp://www.sciencedirect.com/science/article/pii/S1995764516301079
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/328651
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1365676
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.descriptionTo evaluate whether hypoxia inducible factor (HIF-1 alpha) targeting pharmacological drugs, echinomycin, resveratrol and CdCl2, which inhibit HIF-1 alpha stimulation, and mimosine, which enhances the stability of HIF-1 alpha present antileishmanial properties. Methods: The leishmanicidal effect of drugs was evaluated in mouse macrophages and Balb/c mouse model for cutaneous leishmaniosis. Results: Resveratrol and CdCl2, reduced the parasite load [IC50, (27.3 +/- 2.25) mu M and (24.8 +/- 0.95) mu M, respectively]. The IC50 value of echinomycin was (22.7 +/- 7.36) mu M and mimosine did not alter the parasite load in primary macrophages. The macrophage viability IC50 values for resveratrol, echinomycin and CdCl2, and mimosine were >40 mu M, >100 mu M > 200 mu M and>2 000 mu M, respectively. In vivo no differences between cutaneous lesions from control, resveratrol- and echinomycin-treated Balb/c mice were detected. Conclusions: Resveratrol, echinomycin and CdCl2, reduce parasite survival in vitro. The HIF-1 alpha targeting pharmacological drugs require further study to more fully determine their anti-Leishmania potential and their role in therapeutic strategies.
dc.description9
dc.description7
dc.description633
dc.description638
dc.descriptionFundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil
dc.descriptionConselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil [2009/10771-9]
dc.descriptionCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil [301052/2009-3]
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.languageEnglish
dc.publisherElsevier Sci Ltd
dc.publisherOxford
dc.relationAsian Pacific Journal of Tropical Medicine
dc.rightsfechado
dc.sourceWOS
dc.subjectLeishmaniosis
dc.subjectHypoxia Inducible Factor
dc.subjectResveratrol
dc.subjectEchinomycin
dc.subjectCdcl2
dc.subjectMimosine
dc.titleEvaluation Of Hypoxia Inducible Factor Targeting Pharmacological Drugs As Antileishmanial Agents
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución